Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.32 |
| ▸ | MAPT | P10636 | 5/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.32 |
| ▸ | RAB9A | P51151 | 4/20 | 0.32 |
| ▸ | GAA | P10253 | 4/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | USP2 | O75604 | 2/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | PSMD14 | O00487 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19051318 | 0.79 | MAPT (0.40) | MEN1MAPTKMT2ARAB9AGAA | |
| SCHEMBL19038917 | 0.75 | MAPT (0.55) | MEN1MAPTKMT2ARAB9AGAA | |
| SCHEMBL27117352 | 0.72 | MAPT (0.42) | MEN1MAPTKMT2ARAB9AGAA | |
| SCHEMBL24390209 | 0.72 | MAPT (0.40) | MEN1MAPTKMT2ARAB9AGAA | |
| SCHEMBL19038893 | 0.72 | MAPT (0.45) | MEN1MAPTKMT2ARAB9AGAA | |
| SCHEMBL19051259 | 0.72 | APP (0.46) | MEN1MAPTKMT2ARAB9AGAA | |
| SCHEMBL23609195 | 0.72 | MAPT (0.39) | MEN1MAPTKMT2ARAB9AGAA | |
| SCHEMBL22477547 | 0.72 | MAPT (0.35) | MEN1MAPTKMT2ARAB9AGAA | |
| SCHEMBL22477554 | 0.71 | MAPT (0.38) | MEN1MAPTKMT2ARAB9AGAA | |
| SCHEMBL26338677 | 0.69 | MEN1 (0.34) | MEN1MAPTKMT2ARAB9AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11002896-B2 | Retardation film | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2021-05-11 | — | — | US | disclosed |
| US-10029982-B2 | Light absorptive compound, polymer composition containing the compound, polymer film, and cured layer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-07-24 | — | — | US | disclosed |
| US-20170184767-A1 | RETARDATION FILM | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-06-29 | — | — | US | disclosed |
| US-20170183304-A1 | LIGHT ABSORPTIVE COMPOUND, POLYMER COMPOSITION CONTAINING THE COMPOUND, POLYMER FILM, AND CURED LAYER | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170183304-A1 | LIGHT ABSORPTIVE COMPOUND, POLYMER COMPOSITION CONTAINING THE COMPOUND, POLYMER FILM, AND CURED LAYER | MLN, MLEC, VIP | MEN1 738/4885MAPT 487/4885KMT2A 1715/4885 |
| US-10029982-B2 | Light absorptive compound, polymer composition containing the compound, polymer film, and cured layer | MLN, MLEC, VIP | MEN1 738/4885MAPT 487/4885KMT2A 1715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.